Mandate Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Compliance policies and dawn raid manuals should be revised in light of amendments to the Swedish Competition Act

As previously described, the Swedish Competition Act (2008:579) will be amended in several important respects on 4 February 2021. We recommend that you revise your current compliance policies and manuals for dawn raids to ensure adherence with the new rules.
November 25, 2020

Jerker Kjellander is a new partner in Skåne

Dispute resolution expert Jerker Kjellander has been elected as a partner in Vinge’s Skåne office.
November 20, 2020

Amendments to the Swedish Competition Act provide extended powers for the Swedish Competition Authority

Early in 2021, the Swedish Competition Act (2008: 579) will be amended in several important respects. The background to the amendments is Directive (EU) 2019/1 of the European Parliament and of the Council, which aims to harmonize the investigative and sanctioning powers of the European competition authorities in their enforcement of the EU competition rules. Undertakings active in Sweden will be affected by the amendments in several ways.
October 12, 2020